Jesduvroq (daprodustat) — Point32Health

Initial criteria

• Documented diagnosis of anemia due to chronic kidney disease
• Documentation the patient has been receiving dialysis for at least four months prior to treatment initiation with Jesduvroq
• Patient age ≥ 18 years
• Documentation patient is hyporesponsive to erythropoiesis-stimulating agent therapy, defined as a hemoglobin level between 8.0 to 11.5 g/dL following treatment with either epoetin alfa or darbepoetin
• Documentation of adequate iron stores (serum ferritin ≥ 100 mcg/mL OR serum transferrin saturation ≥ 20% within the prior three months, OR currently receiving iron therapy)

Reauthorization criteria

• Documented diagnosis of anemia due to chronic kidney disease
• Patient age ≥ 18 years
• Documentation the patient has experienced a therapeutic response as defined by an increase in hemoglobin from baseline

Approval duration

initial 6 months; reauth 12 months